Biopharmaceutical company Sigilon Therapeutics reported on Thursday the election of David E. Moller, MD as its chief scientific officer.
Most recently, Dr Moller has served in Eli Lilly as vice president of Business Development - Emerging Technology and Innovation at Eli Lilly as well as vice president of its Endocrine and Cardiovascular Research and Clinical Investigation .
Previously, Dr Moller was employed as vice president, Metabolic Disorders at Merck (MSD), which included oversight of the team responsible for the discovery of sitaglipitin (Januvia), leading the global discovery efforts in diabetes and obesity.
Earlier in his career, Dr Moller was part of the faculty of Harvard Medical School.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults